Company Overview
| Stock Name | Ak Medical |
|---|---|
| Stock Code | 01789 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是中國第一家且唯一一家將3D打印技術商業化且應用於骨關節及脊柱置換植入物的醫療器械公司,設計、開發、生產及銷售骨科植入物,專注於髖關節及膝關節置換植入物,亦分銷第三方骨科產品。 |
| Listing Date | 2017-12-20 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 北京市 昌平區科技園區 白浮泉路10號 |
| Business Address (Hong Kong) | 香港 皇后大道東183號 合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | ak-medical.net |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 1.75 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2017-12-07 to 2017-12-12 |
| Global Offering Shares | 250,000,000 shares |
| HK Public Offer Shares (Initial) | 25,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 225,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,000,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 437,500,000 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 5.94B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利约人民币77.3百万元 |
| Period-End Cash Balance | 人民币160.6百万元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2014 | 2015 | 2016 | 2017-06 |
|---|---|---|---|---|
| Revenue | 148,278 | 206,164 | 270,777 | 162,517 |
| Cost of sales | -46,933 | -64,108 | -83,466 | -50,814 |
| Gross profit | 101,345 | 142,056 | 187,311 | 111,703 |
| Other income and gains, net | 1,778 | 823 | 793 | 1,854 |
| Selling and distribution expenses | -17,416 | -28,782 | -36,229 | -19,660 |
| Administrative expenses | -12,377 | -22,262 | -38,115 | -18,276 |
| Operating profit | 57,791 | 72,957 | 93,370 | 57,692 |
| Net finance costs | 2,506 | 2,994 | 1,657 | 478 |
| Profit before tax | 60,297 | 75,951 | 95,027 | 58,170 |
| Income tax expense | -8,576 | -11,044 | -17,701 | -8,120 |
| Profit for the year | 51,721 | 64,907 | 77,326 | 50,050 |
| Profit attributable to owners | 51,721 | 64,907 | 77,326 | 50,050 |
Balance Sheet
| Item | 2014 | 2015 | 2016 | 2017-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 43,161 | 100,094 | 160,597 | 165,628 |
| Trade and bills receivables | 24,048 | 57,861 | 81,530 | 89,721 |
| Inventories | 34,720 | 58,400 | 67,805 | 84,848 |
| Total current assets | 177,037 | 223,973 | 322,457 | 353,406 |
| Total assets | 212,647 | 283,750 | 405,535 | 459,827 |
| Total current liabilities | 51,065 | 100,819 | 99,034 | 127,468 |
| Total liabilities | 56,696 | 106,812 | 111,142 | 139,260 |
| Total equity | 155,951 | 176,938 | 294,393 | 320,567 |
| Equity attributable to owners | 155,951 | 176,938 | 294,393 | 320,567 |
Cash Flow Statement
| Item | 2014 | 2015 | 2016 | 2017-06 |
|---|---|---|---|---|
| Net cash from operating activities | 51,092 | 36,302 | 69,643 | 56,479 |
| Net cash from investing activities | -16,020 | 44,462 | -27,166 | -26,901 |
| Net cash from financing activities | -30,600 | -23,911 | 14,037 | -23,403 |
| Net increase in cash | 4,472 | 56,853 | 56,514 | 6,175 |
| Depreciation of PP&E | 4,276 | 4,641 | 7,865 | 5,178 |
| Amortisation of intangible assets | 247 | 449 | 907 | 588 |
| Purchase of PP&E | -6,063 | -24,367 | -28,371 | -24,363 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 2.64 |
|---|---|
| First Day Open | HK$ 1.75 |
| First Day Change | 50.86% |
| First Day Volume | 214153000.0 |
| First Day Turnover | 456984000.0 |
| Use of Proceeds | 1、約41.0%將主要用于我們常州設施的建設,并在較少程度上升級我們于北京現有的設施,及為常洲設施及我們于北京現有的設施收購新設備;
2、約21.0%將用作開發及升級我們的3D打印產品及醫工交互平臺;
3、約15.0%將用作其他研發活動;
4、約15.0%將用于撥付能夠補充我們的現有產品組合、技術及業務增長的潛在收購及發展戰略聯盟;
5、約8.0%將用作一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Overall Coordinators (1)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Joint Bookrunners (1)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 李志疆 | — |
| Company Secretary | 韓鈺、李昕穎 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 李先生通過喜馬拉亞及配偶權益合共持有約59.53%股份,張斌女士因配偶權益被視為持有約59.53%股份;張朝陽先生通過陽峰持有約6.74%股份;OrbiMed Asia持有約7.50%股份。 |
|---|




